Found: 73
Select item for more details and to access through your institution.
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 2929, doi. 10.3390/cancers16172929
- By:
- Publication type:
- Article
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E226, doi. 10.1002/ajh.27001
- By:
- Publication type:
- Article
Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1607, doi. 10.1002/ajh.26747
- By:
- Publication type:
- Article
Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 877, doi. 10.1002/ajh.26566
- By:
- Publication type:
- Article
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 7, p. 647, doi. 10.1002/ajh.24035
- By:
- Publication type:
- Article
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 12, p. 1085, doi. 10.1002/ajh.23835
- By:
- Publication type:
- Article
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 8, p. 657, doi. 10.3390/cells13080657
- By:
- Publication type:
- Article
Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 5, p. 701, doi. 10.1111/ejh.14161
- By:
- Publication type:
- Article
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 3, p. 178, doi. 10.1111/ejh.13723
- By:
- Publication type:
- Article
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 13, p. 10813, doi. 10.3390/ijms241310813
- By:
- Publication type:
- Article
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 20, p. 12450, doi. 10.3390/ijms232012450
- By:
- Publication type:
- Article
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 15, p. 5406, doi. 10.3390/ijms21155406
- By:
- Publication type:
- Article
P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S139, doi. 10.1016/S2152-2650(21)02314-4
- By:
- Publication type:
- Article
P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S67, doi. 10.1016/S2152-2650(21)02187-X
- By:
- Publication type:
- Article
P-036: Implementation of IgH/k Next Generation Sequencing for Multiple Myeloma Minimal Residual Disease monitoring: advantages in patients' management during daily clinical practice.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S58, doi. 10.1016/S2152-2650(21)02170-4
- By:
- Publication type:
- Article
OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S37, doi. 10.1016/S2152-2650(21)02131-5
- By:
- Publication type:
- Article
OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S34, doi. 10.1016/S2152-2650(21)02127-3
- By:
- Publication type:
- Article
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S35, doi. 10.1016/S2152-2650(21)02129-7
- By:
- Publication type:
- Article
OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02078-4
- By:
- Publication type:
- Article
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S4, doi. 10.1016/S2152-2650(21)02080-2
- By:
- Publication type:
- Article
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
- By:
- Publication type:
- Article
Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
- By:
- Publication type:
- Article
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report.
- Published in:
- 2021
- By:
- Publication type:
- case study
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis", caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e78, doi. 10.1016/j.clml.2019.09.125
- By:
- Publication type:
- Article
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e72, doi. 10.1016/j.clml.2019.09.115
- By:
- Publication type:
- Article
A Maturation Index defines Newly Diagnosed Multiple Myeloma Patients with advanced immunophenotypic and Molecular Differentiation profiles associated with poor prognosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e69, doi. 10.1016/j.clml.2019.09.110
- By:
- Publication type:
- Article
Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e12, doi. 10.1016/j.clml.2017.03.020
- By:
- Publication type:
- Article
A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e11, doi. 10.1016/j.clml.2017.03.019
- By:
- Publication type:
- Article
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e65, doi. 10.1016/j.clml.2017.03.118
- By:
- Publication type:
- Article
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Extramedullary disease in multiple myeloma: a systematic literature review.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 3, p. 1, doi. 10.1038/s41408-022-00643-3
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 64, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
The role of imaging techniques in the management of multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 159, n. 5, p. 499, doi. 10.1111/bjh.12007
- By:
- Publication type:
- Article
New Developments in Myeloma Treatment and Response Assessment.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 9, p. 1331, doi. 10.2967/jnumed.122.264972
- By:
- Publication type:
- Article
Pomalidomide combinations are a safe and effective option after daratumumab failure.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 6569, doi. 10.1007/s00432-023-04637-x
- By:
- Publication type:
- Article
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 8, p. 5227, doi. 10.1007/s10238-023-01205-y
- By:
- Publication type:
- Article
Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 1117, doi. 10.1002/jha2.743
- By:
- Publication type:
- Article
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1208741
- By:
- Publication type:
- Article
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1001048
- By:
- Publication type:
- Article
Thalidomide–dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 6, p. 484, doi. 10.1111/j.1600-0609.2010.01434.x
- By:
- Publication type:
- Article
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 1, p. 31, doi. 10.1111/j.1600-0609.2007.00974.x
- By:
- Publication type:
- Article
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2006, v. 76, n. 5, p. 399, doi. 10.1111/j.0902-4441.2005.t01-1-EJH2520.x
- By:
- Publication type:
- Article
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2005, v. 74, n. 3, p. 212, doi. 10.1111/j.1600-0609.2004.00382.x
- By:
- Publication type:
- Article
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
- Published in:
- European Journal of Haematology, 2004, v. 73, n. 2, p. 98, doi. 10.1111/j.1600-0609.2004.00272.x
- By:
- Publication type:
- Article
In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells.
- Published in:
- European Journal of Haematology, 1999, v. 62, n. 3, p. 143, doi. 10.1111/j.1600-0609.1999.tb01736.x
- By:
- Publication type:
- Article
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 3, p. 496, doi. 10.1111/bjh.17338
- By:
- Publication type:
- Article
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature.
- Published in:
- Microorganisms, 2023, v. 11, n. 11, p. 2699, doi. 10.3390/microorganisms11112699
- By:
- Publication type:
- Article
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45000-z
- By:
- Publication type:
- Article